{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:01:00Z","timestamp":1791568860325,"version":"4.3.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"KWF Dutch Cancer Society"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      For meningiomas that are refractory after local treatments, there are no systemic evidence-based therapeutic options to date. In recent years, somatostatin-targeted radionuclide therapy has emerged as a promising new treatment modality. Recent studies have indicated that intra-arterial administration of [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DOTATATE may increase the tumor absorbed dose. This study aims to assess the efficacy of intra-arterial [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DOTATATE in a cohort of treatment-refractory meningiomas.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>\n                      Retrospective cohort study including patients diagnosed with treatment-refractory meningioma (WHO grade 1\u20133), who had received at least one cycle of intra-arterial [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DOTATATE. Primary outcomes were progression-free survival (PFS) and overall survival (OS). Secondary outcomes included objective response, and safety and toxicity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seventeen patients with a median follow-up duration of 36 months (range: 1\u201357 months) were included. Six-month PFS was 65% (95% CI: 46\u201392%) and 6-month OS was 82% (95% CI: 66\u2013100%). Regarding best objective response, disease control was found in 53% (95% CI: 28\u201377%); with an objective response rate of 24% (95% CI: 7\u201350%). In terms of safety, two patients developed grade 3 anemia, while one patient experienced local necrosis as a result of peripheral embolism, a complication related to angiographic intervention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      In a treatment-refractory meningioma cohort, intra-arterial administration of [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DOTATATE is safe and effective, with an objective response rate of 24%, and survival data that exceed published benchmarks. Prospective controlled studies with larger cohorts and extended follow-up are needed, comparing intra-arterial [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]Lu-DOTATATE to (historic) cohorts receiving intravenous administration are needed.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11060-025-05266-9","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T12:13:11Z","timestamp":1760530391000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy of Intra-arterial [177Lu]Lu-DOTATATE monotherapy for treatment-refractory meningioma"],"prefix":"10.1007","volume":"176","author":[{"given":"A.","family":"El Ghalbouni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. J.","family":"Snijders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Amerein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Tolboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Patt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. J.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. C.","family":"van der Schaaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Lapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8824-8697","authenticated-orcid":false,"given":"A. J. A. T.","family":"Braat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"issue":"Supplement6","key":"5266_CR1","doi-asserted-by":"publisher","first-page":"vi1","DOI":"10.1093\/neuonc\/noae145","volume":"26","author":"M Price","year":"2024","unstructured":"Price M et al (2024) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the united States in 2017\u20132021. Neuro Oncol 26(Supplement6):vi1\u2013vi85","journal-title":"Neuro Oncol"},{"issue":"2","key":"5266_CR2","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1093\/neuonc\/noae170","volume":"27","author":"F Sahm","year":"2025","unstructured":"Sahm F et al (2025) cIMPACT-NOW update 8: clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas. Neuro Oncol 27(2):319\u2013330","journal-title":"Neuro Oncol"},{"issue":"9","key":"5266_CR3","doi-asserted-by":"publisher","first-page":"e383","DOI":"10.1016\/S1470-2045(16)30321-7","volume":"17","author":"R Goldbrunner","year":"2016","unstructured":"Goldbrunner R et al (2016) EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol 17(9):e383\u2013e391","journal-title":"Lancet Oncol"},{"issue":"6","key":"5266_CR4","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1097\/WCO.0000000000001002","volume":"34","author":"T Graillon","year":"2021","unstructured":"Graillon T, Tabouret E, Chinot O (2021) Chemotherapy and targeted therapies for meningiomas: what is the evidence? Curr Opin Neurol 34(6):857\u2013867","journal-title":"Curr Opin Neurol"},{"issue":"6","key":"5266_CR5","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1093\/neuonc\/not330","volume":"16","author":"T Kaley","year":"2014","unstructured":"Kaley T et al (2014) Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. Neuro Oncol 16(6):829\u2013840","journal-title":"Neuro Oncol"},{"key":"5266_CR6","doi-asserted-by":"crossref","unstructured":"Kotecha R et al (2025) Benchmarking the efficacy of salvage systemic therapies for recurrent meningioma: a RANO group systematic review and meta-analysis to guide clinical trial design. Neuro Oncol","DOI":"10.1093\/neuonc\/noaf009"},{"issue":"5","key":"5266_CR7","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1002\/(SICI)1097-0215(19980529)76:5<620::AID-IJC2>3.0.CO;2-S","volume":"76","author":"A Dutour","year":"1998","unstructured":"Dutour A et al (1998) Expression of somatostatin receptor subtypes in human brain tumors. Int J Cancer 76(5):620\u2013627","journal-title":"Int J Cancer"},{"issue":"12","key":"5266_CR8","doi-asserted-by":"publisher","first-page":"3662","DOI":"10.1007\/s00259-024-06783-x","volume":"51","author":"NL Albert","year":"2024","unstructured":"Albert NL et al (2024) Joint EANM\/EANO\/RANO\/SNMMI practice guideline\/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor ligands: version 1.0. Eur J Nucl Med Mol Imaging 51(12):3662\u20133679","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"5266_CR9","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2967\/jnumed.120.249607","volume":"62","author":"C Mirian","year":"2021","unstructured":"Mirian C et al (2021) Somatostatin Receptor-Targeted radiopeptide therapy in Treatment-Refractory meningioma: individual patient data Meta-analysis. J Nucl Med 62(4):507\u2013513","journal-title":"J Nucl Med"},{"issue":"4","key":"5266_CR10","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1007\/s00259-022-06044-9","volume":"50","author":"NS Minczeles","year":"2023","unstructured":"Minczeles NS et al (2023) Efficacy and safety of peptide receptor radionuclide therapy with [(177)Lu]Lu-DOTA-TATE in 15 patients with progressive treatment-refractory meningioma. Eur J Nucl Med Mol Imaging 50(4):1195\u20131204","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"5266_CR11","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.2967\/jnumed.123.266956","volume":"65","author":"S Severi","year":"2024","unstructured":"Severi S et al (2024) Peptide receptor radionuclide therapy in advanced refractory meningiomas: efficacy and toxicity in a long Follow-up. J Nucl Med 65(9):1409\u20131415","journal-title":"J Nucl Med"},{"issue":"4","key":"5266_CR12","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s00259-023-06467-y","volume":"51","author":"SC Ebbers","year":"2024","unstructured":"Ebbers SC et al (2024) Intra-arterial peptide-receptor radionuclide therapy for neuro-endocrine tumour liver metastases: an in-patient randomised controlled trial (LUTIA). Eur J Nucl Med Mol Imaging 51(4):1121\u20131132","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"5266_CR13","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1007\/s00270-019-02262-1","volume":"42","author":"A Braat","year":"2019","unstructured":"Braat A et al (2019) Will (177)Lu-DOTATATE treatment become more effective in salvage meningioma Patients, when boosting somatostatin receptor saturation? A promising case on Intra-arterial administration. Cardiovasc Intervent Radiol 42(11):1649\u20131652","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"3","key":"5266_CR14","doi-asserted-by":"publisher","first-page":"406","DOI":"10.2967\/jnumed.121.262491","volume":"63","author":"EPA Vonken","year":"2022","unstructured":"Vonken EPA et al (2022) Intraarterial administration boosts (177)Lu-HA-DOTATATE accumulation in salvage meningioma patients. J Nucl Med 63(3):406\u2013409","journal-title":"J Nucl Med"},{"issue":"2","key":"5266_CR15","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J et al (2017) Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med 376(2):125\u2013135","journal-title":"N Engl J Med"},{"issue":"1","key":"5266_CR16","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1093\/neuonc\/noy137","volume":"21","author":"RY Huang","year":"2019","unstructured":"Huang RY et al (2019) Proposed response assessment and endpoints for meningioma clinical trials: report from the response assessment in Neuro-Oncology working group. Neuro Oncol 21(1):26\u201336","journal-title":"Neuro Oncol"},{"key":"5266_CR17","unstructured":"US Department of Health and Human Services, National Institute of health, National Cancer Institute. Common terminology criteria for adverse events (CTCAE). Version 5.0., National Institute of health, National Cancer Institute (2017); Accessed March 2025. 2017; US Department of Health and Human Services,. Common terminology criteria for adverse events (CTCAE). Version 5.0. 2017; Accessed March 2025.]. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf"},{"issue":"8","key":"5266_CR18","doi-asserted-by":"publisher","first-page":"5550","DOI":"10.3390\/curroncol29080438","volume":"29","author":"B Salgues","year":"2022","unstructured":"Salgues B et al (2022) Somatostatin receptor theranostics for refractory meningiomas. Curr Oncol 29(8):5550\u20135565","journal-title":"Curr Oncol"},{"issue":"11","key":"5266_CR19","first-page":"1538","volume":"18","author":"K Seystahl","year":"2016","unstructured":"Seystahl K et al (2016) Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE\/-TOC uptake. Neuro Oncol 18(11):1538\u20131547","journal-title":"Neuro Oncol"},{"key":"5266_CR20","doi-asserted-by":"crossref","unstructured":"Hasenauer N et al (2025) SSTR-directed peptide receptor radionuclide therapy for recurrent meningiomas: analysis of safety, efficacy and prognostic factors. Eur J Nucl Med Mol Imaging","DOI":"10.1007\/s00259-025-07336-6"},{"issue":"5","key":"5266_CR21","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1055\/a-1200-0989","volume":"59","author":"M Muther","year":"2020","unstructured":"Muther M et al (2020) Response assessment of somatostatin receptor targeted radioligand therapies for progressive intracranial meningioma. Nuklearmedizin 59(5):348\u2013355","journal-title":"Nuklearmedizin"},{"issue":"6","key":"5266_CR22","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1097\/RLU.0000000000005845","volume":"50","author":"J Zhang","year":"2025","unstructured":"Zhang J et al (2025) Long-term Efficacy, Survival, and toxicity of peptide receptor radionuclide therapy in patients with refractory meningioma. Clin Nucl Med 50(6):508\u2013516","journal-title":"Clin Nucl Med"},{"key":"5266_CR23","first-page":"29","volume":"22","author":"PE Hartrampf","year":"2020","unstructured":"Hartrampf PE et al (2020) Long-term results of multimodal peptide receptor radionuclide therapy and fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma. Clin Transl Radiat Oncol 22:29\u201332","journal-title":"Clin Transl Radiat Oncol"},{"issue":"2","key":"5266_CR24","doi-asserted-by":"publisher","first-page":"278","DOI":"10.4103\/NI.Neurol-India-D-23-00252","volume":"72","author":"AD Puranik","year":"2024","unstructured":"Puranik AD et al (2024) PRRT with Lu-177 DOTATATE in Treatment-Refractory progressive meningioma: initial experience from a Tertiary-Care Neuro-Oncology center. Neurol India 72(2):278\u2013284","journal-title":"Neurol India"},{"issue":"12","key":"5266_CR25","first-page":"1911","volume":"65","author":"A Amerein","year":"2024","unstructured":"Amerein A et al (2024) Intraarterial administration of peptide receptor radionuclide therapy in patients with advanced meningioma: initial safety and efficacy. J Nucl Med 65(12):1911\u20131916","journal-title":"J Nucl Med"},{"issue":"10446","key":"5266_CR26","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"S Singh","year":"2024","unstructured":"Singh S et al (2024) [(177)Lu]Lu-DOTA-TATE plus long-acting octreotide versus high\u2013dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2\u20133, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet 403(10446):2807\u20132817","journal-title":"Lancet"},{"issue":"12","key":"5266_CR27","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","volume":"22","author":"JR Strosberg","year":"2021","unstructured":"Strosberg JR et al (2021) (177)Lu-Dotatate plus long-acting octreotide versus high\u2013dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol 22(12):1752\u20131763","journal-title":"Lancet Oncol"},{"issue":"2","key":"5266_CR28","first-page":"e22392","volume":"14","author":"S Alkassis","year":"2022","unstructured":"Alkassis S et al (2022) Lutetium-177 Dotatate-Induced hemolytic anemia and myelodysplastic syndrome. Cureus 14(2):e22392","journal-title":"Cureus"},{"issue":"6","key":"5266_CR29","first-page":"189","volume":"31","author":"M Kesavan","year":"2016","unstructured":"Kesavan M, Turner JH (2016) Myelotoxicity of peptide receptor radionuclide therapy of neuroendocrine tumors: A decade of experience. Cancer Biother Radiopharm 31(6):189\u2013198","journal-title":"Cancer Biother Radiopharm"},{"issue":"5","key":"5266_CR30","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11916-021-00946-3","volume":"25","author":"M Dominguez","year":"2021","unstructured":"Dominguez M, Malani R (2021) Stroke-Like migraine attacks after radiation therapy (SMART) syndrome: A comprehensive review. Curr Pain Headache Rep 25(5):33","journal-title":"Curr Pain Headache Rep"},{"issue":"1","key":"5266_CR31","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ijrobp.2023.07.015","volume":"118","author":"B Vellayappan","year":"2024","unstructured":"Vellayappan B et al (2024) A systematic review informing the management of symptomatic brain radiation necrosis after stereotactic radiosurgery and international stereotactic radiosurgery society recommendations. Int J Radiat Oncol Biol Phys 118(1):14\u201328","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"5266_CR32","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23(8):1231\u20131251","journal-title":"Neuro Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05266-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-025-05266-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05266-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T12:34:39Z","timestamp":1767702879000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-025-05266-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["5266"],"URL":"https:\/\/doi.org\/10.1007\/s11060-025-05266-9","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"assertion":[{"value":"25 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was waived by both institutional ethics committees, because of the retrospective nature of this study. This study was conducted in line with the principles of the Declaration of Helsinki and all applicable local regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"N. Tolboom is consultant for Telix Pharmaceuticals and Theranova and receives in kind research support from Curium Pharmaceuticals. C. Lapa reports prior consulting activities for Blue Earth Diagnostics Ltd. & Novartis. A.J.A.T. Braat is consultant for Boston Scientific, Terumo, GE Healthcare & Telix Pharmaceuticals, receives research support from Boston Scientific, Telix Pharmaceuticals, Ariceum Therapeutics & Siemens Healthineers. All others authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8"}}